Close Menu

NEW YORK (GenomeWeb) – Cancer Genetics today priced its public offering of more than 13 million shares of its common stock at $.225 per share.

The company expects gross proceeds $3 million from the offering, which includes a 45-day option to its underwriter to purchase up to an additional 2 million shares of common stock at $.225 per share. The offering is expected to close on or about Jan. 14.

HC Wainwright is the sole book-running manager for the offering.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.